A systematic review of the prevalence of Morquio A syndrome: challenges for study reporting in rare diseases
Open Access
- 18 November 2014
- journal article
- review article
- Published by Springer Science and Business Media LLC in Orphanet Journal of Rare Diseases
- Vol. 9 (1), 1-17
- https://doi.org/10.1186/s13023-014-0173-x
Abstract
Morquio A (MPS IVA) is a rare disease characterised by a deficiency of N-acetylgalactosamine-6 sulfatase (GALNS) and presenting with short stature, abnormal gait, cervical spine instability and shortened lifespan. To prepare a systematic review of the prevalence of Morquio A in multiple countries and suggest recommendations for reporting rare diseases. Medline, Medline In-Process, Medline Daily Update, Embase, Cochrane Database of Systematic Reviews, Cochrane Central Register of Controlled Trials, Database of Abstracts of Reviews of Effects, Health Technology Assessment Database and PROSPERO were searched from inception to October 2013 to identify relevant information on the epidemiology of Morquio A. Forty Patient Organisation Representatives (POR) and Key Opinion Leaders (KOL) across 24 countries were contacted for data. Observational studies were included and case reports were excluded. Searches were performed without date or language restriction. Two researchers independently screened and extracted data. Quality of study reporting was assessed using a checklist adapted from STROBE (STrengthening the Reporting of OBservational studies in Epidemiology). Point or birth prevalence was stratified according to diagnostic method and discussed narratively. In total 9,074 records were retrieved from searching and 25 studies were included for data extraction. Twenty out of 40 KOL and POR responded (50%) and 9 provided data (23%). Point prevalence of Morquio A was 1 per 926,000 in Australia, 1 per 1,872,000 in Malaysia and 1 per 599,000 in UK and Morquio (unclassified) was 1 per 323, 000 in Denmark. Birth prevalence of Morquio A (using recommended diagnostic methods) ranged from 1 per 71,000 in UAE to 1 per 500,000 in Japan. All results were compromised by poor study reporting and internal validity. The review highlighted that there is a misunderstanding of the definitions for prevalence and incidence in the field; that studies were poorly reported (diagnostic methods and patient characteristics) and that no suitable quality assessment tool exists. Overestimation and underestimation of prevalence data can occur. Bespoke reporting guidelines and a quality assessment tool specifically for prevalence of rare diseases are recommended.Keywords
This publication has 34 references indexed in Scilit:
- Review of clinical presentation and diagnosis of mucopolysaccharidosis IVAMolecular Genetics and Metabolism, 2013
- Diagnosing mucopolysaccharidosis IVAJournal of Inherited Metabolic Disease, 2013
- Diagnosis of the mucopolysaccharidosesRheumatology, 2011
- Incidence and patterns of inborn errors of metabolism in the Eastern Province of Saudi Arabia, 1983-2008Annals of Saudi Medicine, 2010
- The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studiesJournal of Clinical Epidemiology, 2008
- International Morquio A Registry: Clinical manifestation and natural course of Morquio A diseaseJournal of Inherited Metabolic Disease, 2007
- Keratan sulphate levels in mucopolysaccharidoses and mucolipidosesJournal of Inherited Metabolic Disease, 2004
- Morquio disease: Isolation, characterization and expression of full-length cDNA for human N-acetylgalactosamine-6-sulfate sulfataseBiochemical and Biophysical Research Communications, 1991
- Spondyloepiphyseal dysplasia, corneal clouding, normal intelligence and acid β‐galactosidase deficiencyClinical Genetics, 1976